On August 8, 2025, Protagenic Therapeutics, Inc. announced a restructuring plan to cut costs by $8 million annually, focusing on their highest-priority clinical programs while temporarily suspending preclinical activities. Additionally, the CEO and COO were terminated as part of this transition.